Laxol

Docusate Sodium, the active ingredient in Laxol, is a stool softener presented as a rectal formulation for OTC use. It works by reducing surface tension of the fecal mass, allowing water and fatty acids to penetrate, thereby softening the stool and enabling easier, less painful passage for individuals experiencing constipation.

GNH USA supplies Laxol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and reliable delivery across global markets with full regulatory compliance today.

Laxol (docusate sodium) is used as a stool softener to manage constipation and related bowel conditions. - Constipation: softens stool to facilitate easier passage and reduce straining. - Post‑operative constipation: helps maintain soft stools after surgery when patients should avoid strain. - Hemorrhoidal discomfort: softens stool to lessen irritation and pain associated with hemorrhoids. - Anal fissure: softens stool to reduce trauma during defecation. - Pregnancy‑related constipation: provides gentle relief without harsh stimulant effects.

The most frequently reported reactions to docusate sodium are mild and transient, while rare events may require medical attention.

Common Side Effects: - Abdominal cramping - Nausea - Flatulence - Diarrhea - Rectal burning or irritation

Serious or Rare Side Effects: - Allergic rash or hives - Severe abdominal pain - Rectal bleeding - Electrolyte imbalance - Anaphylaxis

When using Laxol, consider the following precautions to ensure safe and effective use. - Assess bowel habit: confirm that constipation is present before initiating therapy. - Limit duration: avoid prolonged use beyond a few days unless directed by a healthcare professional. - Avoid in obstruction: do not use if there is known intestinal blockage or impaction. - Pregnancy and lactation: consult a physician before use, as safety data are limited. - Monitor for allergic reactions: discontinue and seek medical advice if rash, swelling, or breathing difficulty occurs. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Docusate sodium may interact with certain agents that affect gastrointestinal absorption or stool consistency.

Major Interactions (Avoid): - Mineral oil: may reduce the effectiveness of docusate by coating the stool. - Cholesterol‑binding resins (e.g., cholestyramine, colestipol): can decrease docusate absorption. - Orlistat: may impair the surfactant action of docusate.

Moderate Interactions (Monitor Closely): - Calcium or iron supplements: may bind to docusate and lessen its stool‑softening effect. - High‑fiber products: can alter stool bulk and affect docusate performance. - Other laxatives: concurrent use may increase risk of electrolyte disturbances or diarrhea.